BioCryst Pharma Earnings Estimates, EPS & Revenue | NASDAQ:BCRX

Comments

BioCryst Pharmaceuticals Inc Earnings Estimates

BCRXNASDAQ

Trade with Public

$8.22

-0.16-1.91%

At close: Mar 13, 5:00 PM EST

$8.22

N/A

After Hours: 4:00 PM EST

Overview NewsEarningsOptions Guidance Analyst Ratings Insider Trades Short Interest Government Trades Stock Report

BioCryst Pharma Earnings Estimates, EPS & Revenue | NASDAQ:BCRX

BioCryst Pharma (BCRX) is scheduled to report Q1 earnings on May 4, 2026. Analysts estimate EPS of $0.09 and quarterly revenue of $154.50M.

In the most recent quarter (Q4), BioCryst Pharma reported EPS of $0.06, missing estimates of $0.07 by 0.21%. Revenue came in at $163.28M, exceeding the estimate of $150.54M by 0.08%.

Over the last 4 quarters, BioCryst Pharma has averaged an EPS surprise of 1.55% and a revenue surprise of 0.08%.

Earnings Date

May 4

EPS Estimate

$0.090

Quarterly Revenue Estimate

$154.50M

Annual Revenue
(as of Dec 31)

$874.84M

BioCryst Pharma Earnings History

Analyze the earnings history of BioCryst Pharma using advanced sorting and filters.

Loading calendar...

BioCryst Pharma (BCRX) Earnings Per Share

The chart below shows BioCryst Pharma's reported EPS compared to analyst estimates over recent quarters.

BioCryst Pharma (BCRX) Revenue

The chart below shows BioCryst Pharma's reported revenue compared to analyst estimates over recent quarters.

FAQ

When is BioCryst Pharma (NASDAQ:BCRX) reporting earnings?

BioCryst Pharma (BCRX) is scheduled to report earnings on May 4, 2026. The last reported earnings were for reported on February 26, 2026 for Q4.

What were the latest earnings per share (EPS) for BioCryst Pharma (NASDAQ:BCRX)?

The Actual EPS was $0.06, which missed the estimate of $0.07.

What were BioCryst Pharma’s (NASDAQ:BCRX) revenues?

The Actual Revenue was $163.28M, which beat the estimate of $150.54M.

People Also Watch

Ultragenyx Pharmaceutical Inc

NASDAQ:RARE

$21.33

-0.02%

Sarepta Therapeutics Inc

NASDAQ:SRPT

$16.47

0.43%

Ascentage Pharma Group International

NASDAQ:AAPG

$23.70

-2.99%

Syndax Pharmaceuticals Inc

NASDAQ:SNDX

$23.40

-0.43%

Day One Biopharmaceuticals Inc

NASDAQ:DAWN

$21.26

-0.21%

Tango Therapeutics Inc

BioCryst Pharma Earnings Estimates, EPS & Revenue | NASDAQ:BCRX

BioCryst Pharma (BCRX) is scheduled to report Q1 earnings on May 4, 2026. Analysts estimate EPS of $0.09 and quarterly revenue of $154.50M.

In the most recent quarter (Q4), BioCryst Pharma reported EPS of $0.06, missing estimates of $0.07 by 0.21%. Revenue came in at $163.28M, exceeding the estimate of $150.54M by 0.08%.

Over the last 4 quarters, BioCryst Pharma has averaged an EPS surprise of 1.55% and a revenue surprise of 0.08%.

Earnings Date

May 4

EPS Estimate

$0.090

Quarterly Revenue Estimate

$154.50M

Annual Revenue
(as of Dec 31)

$874.84M